Physician profile
Tabitha J Hall
NPI 1205281722
$1,923.05
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $948 · 2022: $641 · 2023: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $334.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $333.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $759.36 | 2021 | |
| Atricure, INC. | $343.51 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $281.46 | 2021-2023 | Xarelto |
| Amgen INC. | $135.64 | 2021-2023 | Repatha |
| Ethicon US, LLC | $74.40 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.55 | 2022-2023 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.59 | 2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $48.09 | 2022 | |
| Stryker Corporation | $46.42 | 2023 | Spy-Phi System |
| Medtronic, INC. | $45.03 | 2021-2023 | Corevalve Evolut R |
| Actelion Pharmaceuticals US, INC. | $36.86 | 2022-2023 | Uptravi, Opsumit |
| Esperion Therapeutics, INC. | $28.03 | 2022-2023 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $12.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.